NCT07388420 Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis
| NCT ID | NCT07388420 |
| Status | Recruiting |
| Phase | — |
| Sponsor | General Hospital of Shenyang Military Region |
| Condition | Hypertriglyceridemia Induced Acute Pancreatitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-01-02 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-01-02 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The severity of hypertriglyceridemia induced acute pancreatitis (HTG-AP) is closely related to the serum triglyceride (TG) levels. The higher the TG levels, the greater the risk of developing severe acute pancreatitis (SAP). Previous expert consensus has pointed out that the key to treating HTG-AP is to rapidly lower serum TG levels to below 5.65 mmol/L. Evolocumab is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, which is often used to treat familial hypercholesterolemia, mixed dyslipidemia and atherosclerotic cardiovascular disease. At the same time, evolocumab also has the effect of reducing TG and may provide a feasible option for the management of HTG-AP. However, its efficacy and safety in reducing TG in patients with HTG-AP remain controversial. This study is a multicenter randomized controlled trial to evaluate the efficacy and safety of adding evolocumab to conventional lipid-lowering therapy in patients with HTG-AP.
Eligibility Criteria
Inclusion Criteria: * Age 18\~75 years * Patients with HTG-AP * Mixed hyperlipidemia * Sign the informed consent form Exclusion Criteria: * Patients who have received lipid-lowering drugs or blood purification treatment within one week before enrollment * Patients who have used evolocumab within one month before enrollment * Patients who are accompanied by diseases that can seriously affect the survival * Patients who have participated in the clinical research of other drugs within one month * Patients who are pregnant or breastfeeding * Patients with allergic asthma, allergic urticaria, eczema, and those who have a clear history of multiple drug and food allergies * Other circumstances that researchers consider not suitable for participation in this study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07388420 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Hypertriglyceridemia Induced Acute Pancreatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07388420 currently recruiting?
Yes, NCT07388420 is actively recruiting participants. Contact the research team at xingshunqi@126.com for enrollment information.
Where is the NCT07388420 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT07388420 clinical trial?
NCT07388420 is sponsored by General Hospital of Shenyang Military Region. The trial plans to enroll 60 participants.